Introduction: The aim of this review is to overview the pharmacological features of
neuroleptics experienced in the treatment of Huntington's disease (HD) symptoms. Despite a …

Despite advances in understanding the pathophysiology of Huntington's disease (HD), there
are currently no effective pharmacological agents available to treat core symptoms or to stop …

Huntington disease (HD) is a chronic, genetic, neurodegenerative disease for which there is
no cure. The main symptoms of HD are abnormal involuntary movements (chorea and …

ObjectiveTo evaluate the safety (primary objective) and efficacy (secondary objective) of (−)-
OSU6162 in Huntington's disease (HD). MethodsIn a double-blind, cross-over trial, patients …

A method of treating a human patient afflicted with Huntington's disease, comprising
periodically orally administering to the patient a pharmaceutical composition comprising …

This invention provides a method of improving cognitive function in a subject comprising
periodically administering to the subject an amount of pridopidine or a pharmaceuti cally …

Treatment-limiting motor complications occur in patients with Parkinson's disease after
chronic levodopa (l-DOPA) treatment, and represent an unmet medical need. We examined …

Introduction Pridopidine is a highly selective sigma-1 receptor (S1R) agonist in development
for the treatment of Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS) …

Introduction: Huntington's disease is a rare dominantly-inherited neurodegenerative disease
with motor, cognitive and behavioral manifestations. It results from an expanded unstable …

In this issue the Huntington's Disease (HD) ACR-16 Randomized Trial (HART) investigators
of the Huntington Study Group (www. huntington-studygroup. org) report a formally negative …